Profile

ProteinQure has built the best computational platform for designing peptides for extra-cellular targets. Its platform has been validated (in-vivo and with unprecedented in-vitro characteristics) with three top 25 pharma companies in their experimental assays. It is the only computational platform capable of designing peptides with the full complement of non-canonical amino acids, so that our peptides are 100x better than natural peptide ligands. For its own internal programs, ProteinQure uses the novel peptides to help deliver payloads in a tissue-specific manner. Peptides are ideal for delivery of different payloads like radioisotopes and gene therapy since they are tissue-specific and easier to ProteinQure has built the best computational platform for designing peptides for extra-cellular targets. Its platform has been validated (in-vivo and with unprecedented in-vitro characteristics) with three top 25 pharma companies in their experimental assays. It is the only computational platform capable of designing peptides with the full complement of non-canonical amino acids, so that our peptides are 100x better than natural peptide ligands. For its own internal programs, ProteinQure uses the novel peptides to help deliver payloads in a tissue-specific manner. Peptides are ideal for delivery of different payloads like radioisotopes and gene therapy since they are tissue-specific and easier to manufacture. Its lead program for Trodelvy-resistant TNBC has begun IND-enabling studies, it also has exciting in-vivo POC for siRNA delivery to CNS.


Event details

Date: June 3 - 6, 2024

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

42 in total